HRTX earnings analysis
What we found in HRTX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Heron’s Q2 revenue was $37.666 million, modestly above the prior-year quarter and materially above Q1, but profitability remained weak: gross margin fell 4.2 percentage points year over year to 69.3%, operating margin was negative 5.4%, and diluted EPS was a $0.03 loss. Acute Care growth of 43.9% was offset by a 15.9% Oncology decline caused by continued competitive pressure. Liquidity improved operationally, with six-month operating cash use declining to $3.8 million, but the company faces a $17.5 million debt prepayment, reduced borrowing availability, adverse CINVANTI patent rulings and an ongoing strategic review.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Rebounded Sequentially
- Net product sales were $37.666 million, up 1.3% from $37.200 million in the prior-year quarter and up 7.6% from $35 million in Q1 2026.
- Acute Care Growth Accelerated
- Acute Care sales increased 43.9% year over year to $15.333 million, driven by higher units sold, increased market share and new customers for ZYNRELEF and APONVIE.
- Sequential Operating Improvement
- Operating margin improved sequentially to negative 5.4% from negative 13.7% in Q1 2026, while general and administrative expense fell 22.1% year over year to $11.276 million.
- Operating Cash Burn Declined
- Operating cash use for the first six months fell 81.0% year over year to $3.8 million from $19.7 million, primarily due to variability in working-capital payments.
- Liquidity Expected for One Year
- Management stated that $42.7 million of cash, cash equivalents and short-term investments is expected to fund anticipated cash requirements for at least one year from issuance of the financial statements, subject to operating-plan assumptions.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Debt Amendment Tightens Liquidity
- On August 7, 2026, the company amended its Working Capital Facility Agreement to require up to $17.5 million of principal prepayments, eliminate future availability of $20.0 million in tranche 2 and $20.0 million in tranche 3, and revise financial covenants effective August 31, 2026.
- CINVANTI Patent Protection Weakened
- A June 1, 2026 court decision held asserted claims of the '255 and '520 CINVANTI patents invalid and found 10 other asserted patents not infringed; Heron appealed on June 30, 2026, while a new Long Grove generic CINVANTI application was disclosed on June 26, 2026 and litigated on August 7, 2026.
- Strategic Review Adds Uncertainty
- The company disclosed on August 10, 2026 that it is considering strategic alternatives with no set timetable, warning that the process could adversely affect employees, customers, lenders and execution of operational initiatives, and could increase stock-price volatility.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.03
- Gross margin
- 69.3%
- Operating margin
- -5.4%
- Segment
- Acute Care net product sales: $15.333 million, up 43.9% year over year.
- Segment
- Oncology net product sales: $22.333 million, down 15.9% year over year.
- Segment
- Total net product sales: $37.666 million, up from $37.200 million year over year.
What they said about what is next.
The 10-Q does not provide new quantitative revenue or EPS guidance. The prior $173 million-$183 million 2026 revenue outlook is not reaffirmed in this filing; management instead disclosed on August 10, 2026 that it is considering strategic alternatives with no set timetable.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 11, 2026
- Heron Therapeutics reported a decline in revenue for Q1 2026, with net product sales of $34.7 million, missing analyst estimates of $36.6 million. The diluted EPS also fell to a loss of $0.04, worse than the anticipated…
- 10-K · February 26, 2026
- Heron’s 10‑K presents a commercial-stage biotech with a stable quarterly revenue run-rate (~$37–$41M per quarter in 2025) and a product portfolio spanning acute care (ZYNRELEF, APONVIE) and oncology (CINVANTI, SUSTOL).…
- 10-Q · August 8, 2025
- Heron reported Q2 net product sales of $37.2M, up 3.3% year-over-year but down versus Q1 2025 (Q1 implied $38.903M). Gross margin expanded to 73.5% and operating loss narrowed versus Q2 2024, but the company swung back…
- 10-Q · May 6, 2025
- Heron reported Q1 2025 net product sales of $38.903M (vs. $34.670M in Q1 2024) and returned to profitability with net income of $2.635M and diluted EPS of $0.01 (vs. net loss $(3.160)M and diluted loss $(0.02) in Q1…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing HRTX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever